Related references
Note: Only part of the references are listed.Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM
Tobias Lanz et al.
NATURE (2022)
Longitudinal Analysis Suggests Epstein--Barr as Cause of Multiple Sclerosis
[Anonymous]
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study
Robert Zivadinov et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)
Revisiting the antiviral theory to explain interferon-beta's effectiveness for relapsing multiple sclerosis
Nahad Sedaghat et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)
Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment
Linn Persson Berg et al.
BMJ NEUROLOGY OPEN (2022)
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
Kjetil Bjornevik et al.
SCIENCE (2022)
EBNA-1 titer gradient in families with multiple sclerosis indicates a genetic contribution
Julia Y. Mescheriakova et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis
Robert Zivadinov et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients
S. Wergeland et al.
EUROPEAN JOURNAL OF NEUROLOGY (2016)
Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis
Fabiana Rizzo et al.
IMMUNOLOGY AND CELL BIOLOGY (2016)
Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis
Silje Kvistad et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Multiple sclerosis therapy and Epstein-Barr virus antibody titres
Joel Raffel et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)
Comparison of two commercial ELISA systems for evaluating anti-EBNA1 IgG titers
Ruth Dobson et al.
JOURNAL OF MEDICAL VIROLOGY (2013)
ω-3 Fatty Acid Treatment in Multiple Sclerosis (OFAMS Study) A Randomized, Double-Blind, Placebo-Controlled Trial
Oivind Torkildsen et al.
ARCHIVES OF NEUROLOGY (2012)
EBV-specific immune responses in patients with multiple sclerosis responding to IFNβ therapy
Manuel Comabella et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment
Kristin I. Loken-Amsrud et al.
NEUROLOGY (2012)
Interferon-β mechanisms of action in multiple sclerosis
Suhayl Dhib-Jalbut et al.
NEUROLOGY (2010)
Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis
Peter Sundstrom et al.
JOURNAL OF NEUROIMMUNOLOGY (2009)
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI
R. A. Farrell et al.
NEUROLOGY (2009)